Immunomic Therapeutics’ Collaborator, University of Florida Presents New Clinical Data from ATTAC-II Study in GBM at the 2019 Society for Neurology (SNO) Annual Meeting

On November 20, 2019 Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, reported that Duane Mitchell, MD, Ph.D., a University of Florida professor of neurosurgery and co-director of the Preston A. Wells Jr. Center for Brain Tumor Therapy, and his team will present new clinical data at the 2019 Society for Neurology (SNO) Annual Meeting being held in Phoenix, Arizona Nov. 20-24, 2019 (Press release, Immunomic Therapeutics, NOV 20, 2019, View Source [SID1234551572]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data being presented at the SNO meeting are from a Phase 2 clinical trial (ATTAC-II) evaluating the efficacy of autologous CMV pp65-LAMP RNA pulsed dendritic cell vaccines mixed with GM-CSF and administered during cycles of adjuvant dose-intensified temozolomide (NCT02465268). The results demonstrate that a CMV pp65-LAMP RNA-pulsed DC vaccination was associated with positive immunologic and clinical response in a patient with MGMT unmethylated midline glioblastoma (GBM).

"The new clinical data to be presented demonstrates the potential impact of our UNITE technology platform and will help validate our therapeutic approach utilizing vaccines to treat difficult cancers like glioblastoma," said Dr. Teri Heiland, Chief Scientific Officer of Immunomic Therapeutics, Inc. "We are encouraged by the immunological response shown with this patient and we look forward to Dr. Mitchell’s presentation of these positive findings at the SNO meeting."

SNO posters – presentation details:

Title: "(ATIM-15) Sustained complete radiographic response and prolonged systemic immune activation in a patient with MGMT unmethylated midline glioblastoma receiving CMV pp65-LAMP RNA-pulsed dendritic cell vaccines"

Category: Adult Clinical Trials – Immunologic

Date and Time: Saturday, Nov 23rd, 5:00 PM – 7:00 PM

Location: Ballroom Lawn, JW Marriott Desert Ridge, Phoenix, Arizona

Title: "(ATIM-34) Single-cell RNA sequencing reveals dynamic immune response changes in glioblastoma patient with durable complete response to CMV pp65-LAMP RNA-pulsed dendritic vaccines
Category: Adult Clinical Trials – Immunologic

Date and Time: Friday, Nov 22nd, 7:30 PM – 9:30 PM

Location: Ballroom Lawn, JW Marriott Desert Ridge, Phoenix, Arizona

The abstracts for University of Florida’s posters at SNO can be found on the following meeting site: View Source and also have been published online in the journal "Neuro-Oncology" by Oxford Academic and can be found here: View Source

About UNITE

ITI’s investigational UNITE platform, or UNiversal Intracellular Targeted Expression, works by fusing pathogenic antigens with the Lysosomal Associated Membrane Protein, an endogenous protein in humans, for immune processing. In this way, ITI’s vaccines (DNA or RNA) have the potential to utilize the body’s natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach could put UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. UNITE is currently being employed in Phase II clinical trials as a cancer immunotherapy. ITI is also collaborating with academic centers and biotechnology companies to study the use of UNITE in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response.

Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoon’s BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration

On November 20, 2019 Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, and AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical company, reported an exclusive worldwide option and license transaction for HPN217, Harpoon’s B cell maturation antigen (BCMA)-targeting Tri-specific T cell Activating Construct (TriTAC), and an expansion of their existing discovery collaboration for up to six additional targets (Press release, Harpoon Therapeutics, NOV 20, 2019, View Source [SID1234551561]). These agreements build upon the discovery collaboration established by the two companies in October 2017 and are expected to advance and broaden the use of Harpoon’s proprietary TriTAC platform. The TriTAC platform produces novel T cell engagers targeting both solid tumors and hematologic malignancies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Harpoon has built a unique and proprietary biologics platform that utilizes the cancer patient’s own immune system to attack cancer. HPN217, targeting BCMA, is poised to advance to clinical development for the treatment of multiple myeloma", stated Gerald McMahon, Ph.D., President and Chief Executive Officer of Harpoon. "We believe AbbVie is the ideal partner for Harpoon to support the advancement of our BCMA program given the commercial focus of AbbVie in the treatment of this cancer. In addition, we look forward to expanding our discovery collaboration to include up to six additional molecular targets."

"Harpoon’s BCMA TriTAC holds promise for myeloma patients, and their novel drug development engine, combined with AbbVie’s development expertise, has the potential to generate innovative new medicines for patients with cancer," said Mohit Trikha, Ph.D., Vice President, Head, Oncology Early Development and AbbVie Bay Area Site Head. "Our collaboration with Harpoon has been productive and we look forward to further strengthening this collaboration."

Relating to the HPN217 license agreement, Natalie Sacks, M.D., Chief Medical Officer of Harpoon Therapeutics notes, "As our pipeline of initial TriTAC clinical candidates advance in prostate and ovarian

cancers, we are thrilled to partner with AbbVie in pursuit of therapies geared towards hematologic cancers. With our efforts and expertise combined, we look forward to the initiation of our planned Phase 1/2 clinical trial with HPN217 in patients with multiple myeloma."

Under the terms of the license and option agreement, Harpoon granted to AbbVie an option to license worldwide exclusive rights to HPN217. Harpoon will be responsible for development of HPN217 through Phase 1/2 clinical trials. Upon exercise of the option, AbbVie will conduct all future clinical development, manufacturing and commercialization activities. AbbVie may exercise its option to license HPN217 after completion of the Phase 1/2 clinical trial. The license and option agreement represents a potential transaction value of up to $510 million in upfront, option and milestone payments, plus royalties on global commercial sales.

Under the terms of the expanded discovery collaboration agreement, AbbVie will receive worldwide exclusive rights to develop and commercialize two new TriTAC molecules engineered for two selected targets. AbbVie has the option to select up to four additional targets for a total of up to six new targets. For each selected target under the Amended Discovery agreement, Harpoon is eligible to receive up to $310 million in upfront and potential development, regulatory and commercial milestone payments, plus royalties on global commercial sales. Consistent with the existing discovery collaboration agreement, Harpoon and AbbVie will conduct certain initial research and discovery activities for each designated target, after which AbbVie will be solely responsible for further development and commercialization efforts.

BrightGene Completes $74 Million Shanghai Star Board IPO; Trades 141% Higher

On November 20, 2019 Suzhou’s BrightGene Bio-Medical reported that completed a $74 million IPO on the Shanghai Star Exchange and climbed 141% higher in its first trading session, giving the company a market capitalization of $1.8 billion (Press release, ChinaBio, NOV 20, 2019, View Source [SID1234551555]). Founded in 2001, BrightGene develops novel drugs as well as hard-to-make generics, APIs and finished drugs. The company is developing immunoncology treatments, oral GLP-1RA peptides for type 2 diabetes, antibody drug conjugates for solid tumors, and novel non-antibody dependent tumor targeting conjugates for brain cancer and solid tumor brain-metastases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Hope4Cancer™ Treatment Centers To Launch ‘Eight Days’ The First Reality Show About Alternative Ways To Fight Cancer

On November 20, 2019 In honor of National Lung Cancer Awareness month, Hope4Cancer Treatment Centers reported Eight Days, a groundbreaking reality TV series that tells the stories of five cancer patients and their journey using alternative cancer treatments that are working (Press release, Hope4cancer, NOV 20, 2019, View Source [SID1234551554]). The first reality TV series of its kind, Eight Days, is set to premiere on the FYI Network on January 4, 2020 and will give viewers an inside look at what healing from cancer is really like, as well as highlight new integrative cancer treatment options.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Antonio Jimenez, Hope4Cancer Founder and Chief Medical Officer, prepares to launch the first of its kind docuseries on cancer called Eight Days. The 10-episode program will air on the FYI Network and follows 5 patients and their alternative treatments at the Hope4Cancer Center.
Dr. Antonio Jimenez, Hope4Cancer Founder and Chief Medical Officer, prepares to launch the first of its kind docuseries on cancer called Eight Days. The 10-episode program will air on the FYI Network and follows 5 patients and their alternative treatments at the Hope4Cancer Center.
"Eight Days examines the lives of five diverse individuals living with different stages of cancer and the experts who guide them on their healing journey. From physical, emotional, and spiritual healing, as well as, how to treat the root of cancer instead of the symptoms. We also see the latest breakthroughs in non-toxic cancer treatments that are having real impact on the disease," explained Hope4Cancer Founder and Chief Medical Officer, Dr. Antonio Jimenez.

The five patients highlighted in the series include Kate Malvenan, diagnosed with Stage 4 Lung Cancer. The 39-year old solo mother from Australia’s Gold Coast is determined to beat cancer for her 3-year-old daughter, Annabelle. At the time of her original diagnosis, Kate was given only six months to live, with cancer spreading throughout her spine, hips, ribs, shoulder, and liver. Refusing to give up, she arrives on Eight Days ready to embrace change with the spirit of a warrior and the strength of a mother.

"If I wasn’t a mom, I think I would have taken the diagnosis and just handled it gracefully. But being a parent, I’ve taken the gloves off, and I’m ready to fight this," says Kate Malvenan, cancer patient, Eight Days.

Additional patients include:

43-year old Carrie Crary, an active, health-conscious nurse who battles Breast Cancer for the second time.
66-year old Jose Fernandez, a pastor diagnosed with Prostate Cancer.
41-year old Nicole Randle who works to overcome Stage 3 Ovarian Cancer.
57-year old Janine Jannicelli who is diagnosed with Breast Cancer.
"We partnered with film producer, Charles Mattocks, to help us share our patients’ stories, because we know of his work as a health advocate and appreciate his passion for investigative storytelling," added Jimenez.

Charles Mattocks is an award-winning film producer who garnered media attention for his first docuseries, Reversed, where he focused on the health effects of diabetes. With over 1.7 million cancer diagnoses documented per year in the U.S. alone, Mattock takes on a health topic where the show’s content and information have the power and potential to affect millions of lives.

"It’s a show unlike anything that’s been seen before, with cancer survivors who share it all and experts who lovingly guide them to health and healing," stated Jimenez.

For more information, visit the Hope4Cancer Eight Days site.

Media Preview Trailer (is free and clear for use for broadcast, online, digital and social media postings, please courtesy "Eight Days/Hope4Cancer")

Caris Life Sciences to Present at 31st Annual Piper Jaffray Healthcare Conference

On November 20, 2019 Caris Life Sciences, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, reported that Brian J. Brille, Vice Chairman of the Company, will present at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019, at 12:50 p.m. Eastern Time at Lotte New York Palace Hotel, Kennedy 1 Room, in New York City (Press release, Caris Life Sciences, NOV 20, 2019, View Source [SID1234551552]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Brille will present a corporate overview and discuss recent expansion and development progress that positions the Company to further extend its leadership in precision medicine. He will also take questions from the audience following the presentation.

Investors attending the conference who would like to schedule a one-on-one meeting with Caris executives may do so by contacting their Piper Jaffray representative.